Moreover, viable Mo-DCs were also correlated with the percentage of IL-17A-expressing Mo-DCs in LCH patients (Figure 2F, mean 35% and range 10-55% for survival). This evidence concerns the gene IL17A and Langerhans cell histiocytosis.